Sebastian Igelmann

Sebastian Igelmann


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2013 in Genes & Development
Verified
Journal Article
Open access
PDF file
XDXavier Deschênes-Simard
Xavier Deschênes-Simard
MGMarie-France Gaumont-Leclerc
Marie-France Gaumont-Leclerc
VBVéronique Bourdeau
Véronique Bourdeau
FLFrédéric Lessard
Frédéric Lessard
OMOlga Moiseeva
Olga Moiseeva
Gerardo FerbeyreGerardo Ferbeyre
Gerardo Ferbeyre
Constitutive activation of growth factor signaling pathways paradoxically triggers a cell cycle arrest known as cellular senescence. In primary cells expressing oncogenic ras, this mechanism effectively prevents cell transformation. Surprisingly, attenuation of ERK/MAP kinase signaling by genetic inactivation of Erk2, RNAi-mediated knockdown of ERK1 or ERK2, or MEK inhibitors prevented the activation of the senescence mechanism, allowing oncogenic ras to transform primary cells. Mechanistically, ERK-mediated senescence involved the proteasome-dependent degradation of proteins required for cell cycle progression, mitochondrial functions, cell migration, RNA metabolism, and cell signaling. This senescence-associated protein degradation (SAPD) was observed not only in cells expressing ectopic ras, but also in cells that senesced due to short telomeres. Individual RNAi-mediated inactivation of SAPD targets was sufficient to restore senescence in cells transformed by oncogenic ras or trigger senescence in normal cells. Conversely, the anti-senescence viral oncoproteins E1A, E6, and E7 prevented SAPD. In human prostate neoplasms, high levels of phosphorylated ERK were found in benign lesions, correlating with other senescence markers and low levels of STAT3, one of the SAPD targets. We thus identified a mechanism that links aberrant activation of growth signaling pathways and short telomeres to protein degradation and cellular senescence.

25 June 2018 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
FLFrédéric Lessard
Frédéric Lessard
SISebastian Igelmann
Sebastian Igelmann
CTChristian Trahan
Christian Trahan
GHGeneviève Huot
Geneviève Huot
ESEmmanuelle Saint-Germain
Emmanuelle Saint-Germain
Gerardo FerbeyreGerardo Ferbeyre
Gerardo Ferbeyre

25 September 2019 in Cancers
Verified
Journal Article
Open access
PDF file
SISebastian Igelmann
Sebastian Igelmann
HNHeidi Neubauer
Heidi Neubauer
Gerardo FerbeyreGerardo Ferbeyre
Gerardo Ferbeyre
The Signal Transducer and Activator of Transcription (STAT)3 and 5 proteins are activated by many cytokine receptors to regulate specific gene expression and mitochondrial functions. Their role in cancer is largely context-dependent as they can both act as oncogenes and tumor suppressors. We review here the role of STAT3/5 activation in solid cancers and summarize their association with survival in cancer patients. The molecular mechanisms that underpin the oncogenic activity of STAT3/5 signaling include the regulation of genes that control cell cycle and cell death. However, recent advances also highlight the critical role of STAT3/5 target genes mediating inflammation and stemness. In addition, STAT3 mitochondrial functions are required for transformation. On the other hand, several tumor suppressor pathways act on or are activated by STAT3/5 signaling, including tyrosine phosphatases, the sumo ligase Protein Inhibitor of Activated STAT3 (PIAS3), the E3 ubiquitin ligase TATA Element Modulatory Factor/Androgen Receptor-Coactivator of 160 kDa (TMF/ARA160), the miRNAs miR-124 and miR-1181, the Protein of alternative reading frame 19 (p19ARF)/p53 pathway and the Suppressor of Cytokine Signaling 1 and 3 (SOCS1/3) proteins. Cancer mutations and epigenetic alterations may alter the balance between pro-oncogenic and tumor suppressor activities associated with STAT3/5 signaling, explaining their context-dependent association with tumor progression both in human cancers and animal models.

1 September 2021 in Molecular Cell
Verified
Journal Article
Closed access
SISebastian Igelmann
Sebastian Igelmann
FLFrédéric Lessard
Frédéric Lessard
OUOro Uchenunu
Oro Uchenunu
JBJacob Bouchard
Jacob Bouchard
AFAna Fernandez-Ruiz
Ana Fernandez-Ruiz
Gerardo FerbeyreGerardo Ferbeyre
Gerardo Ferbeyre

1 January 2025 in Nature
Verified
Journal Article
Open access
PDF file
GDGinevra Doglioni
Ginevra Doglioni
JFJuan Fernández-García
Juan Fernández-García
SISebastian Igelmann
Sebastian Igelmann
PAPatricia Altea-Manzano
Patricia Altea-Manzano
ABArnaud Blomme
Arnaud Blomme
SFSarah-Maria Fendt
Sarah-Maria Fendt
Lung metastases occur in up to 54% of patients with metastatic tumours1,2. Contributing factors to this high frequency include the physical properties of the pulmonary system and a less oxidative environment that may favour the survival of cancer cells3. Moreover, secreted factors from primary tumours alter immune cells and the extracellular matrix of the lung, creating a permissive pre-metastatic environment primed for the arriving cancer cells4,5. Nutrients are also primed during pre-metastatic niche formation6. Yet, whether and how nutrients available in organs in which tumours metastasize confer cancer cells with aggressive traits is mostly undefined. Here we found that pulmonary aspartate triggers a cellular signalling cascade in disseminated cancer cells, resulting in a translational programme that boosts aggressiveness of lung metastases. Specifically, we observe that patients and mice with breast cancer have high concentrations of aspartate in their lung interstitial fluid. This extracellular aspartate activates the ionotropic N-methyl-d-aspartate receptor in cancer cells, which promotes CREB-dependent expression of deoxyhypusine hydroxylase (DOHH). DOHH is essential for hypusination, a post-translational modification that is required for the activity of the non-classical translation initiation factor eIF5A. In turn, a translational programme with TGFβ signalling as a central hub promotes collagen synthesis in lung-disseminated breast cancer cells. We detected key proteins of this mechanism in lung metastases from patients with breast cancer. In summary, we found that aspartate, a classical biosynthesis metabolite, functions in the lung environment as an extracellular signalling molecule to promote aggressiveness of metastases.

6 January 2019 in Aging Cell
Verified
Journal Article
Open access
PDF file
XDXavier Deschênes‐Simard
Xavier Deschênes‐Simard
MPMaxime Parisotto
Maxime Parisotto
MRMarie‐Camille Rowell
Marie‐Camille Rowell
BCBenjamin Le Calvé
Benjamin Le Calvé
SISebastian Igelmann
Sebastian Igelmann
Gerardo FerbeyreGerardo Ferbeyre
Gerardo Ferbeyre
Most cancers arise in old individuals, which also accumulate senescent cells. Cellular senescence can be experimentally induced by expression of oncogenes or telomere shortening during serial passage in culture. In vivo, precursor lesions of several cancer types accumulate senescent cells, which are thought to represent a barrier to malignant progression and a response to the aberrant activation of growth signaling pathways by oncogenes (oncogene toxicity). Here, we sought to define gene expression changes associated with cells that bypass senescence induced by oncogenic RAS. In the context of pancreatic ductal adenocarcinoma (PDAC), oncogenic KRAS induces benign pancreatic intraepithelial neoplasias (PanINs), which exhibit features of oncogene‐induced senescence. We found that the bypass of senescence in PanINs leads to malignant PDAC cells characterized by gene signatures of epithelial‐mesenchymal transition, stem cells, and mitochondria. Stem cell properties were similarly acquired in PanIN cells treated with LPS, and in primary fibroblasts and mammary epithelial cells that bypassed Ras‐induced senescence after reduction of ERK signaling. Intriguingly, maintenance of cells that circumvented senescence and acquired stem cell properties was blocked by metformin, an inhibitor of complex I of the electron transport chain or depletion of STAT3, a protein required for mitochondrial functions and stemness. Thus, our studies link bypass of senescence in premalignant lesions to loss of differentiation, acquisition of stemness features, and increased reliance on mitochondrial functions.